About Indegene Limited
Data last updated: 05 January 2026
Indegene Limited is a public limited company based in Bangalore, Karnataka, India. It specialises in consumer and professional services, a part of the broader travel and hospitality sector. Incorporated on 16 October 1998, the company has been in operation for over 28 years.
Registered with ROC Bangalore under CIN L73100KA1998PLC102040. Listed.
Capital: an authorised share capital of ₹80 Cr and a paid-up capital of ₹48.09 Cr. Formerly known as Ndegene Lifesystems Private Limited and Indegene Lifesystems Private Limited. It is led by directors including Pravin Udhyavara Bhadya Rao and Mark Frank Dzialga.
Last AGM: 26 June 2025. Financial statements filed for year ended 31 March 2025. Office: Aspen G4 3Rd Floor Manyata Embassy Business Park Outer Ring Road Nagavara, Bangalore, Karnataka, India – 560045.
As per the financials filed for FY 2025, the company reported a revenue of ₹2,946.5 Cr, a growth of 11% compared to the previous year.
The company has a workforce of approximately 4,628 employees as per the latest available data.
The company is associated with 1 brand - Indegene. As per MCA filings, the company has open charges of ₹85.5 Cr and satisfied charges of ₹25.45 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website indegene.com.
-
Email*****@*****.com
-
Telephone+91-****-******
-
Website
-
Social Media
-
Registered AddressAspen G4 3Rd Floor Manyata Embassy Business Park Outer Ring Road Nagavara, Bangalore, Karnataka, India – 560045
-
IndustryTravel and Hospitality, Consumer Professional Services
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Indegene Limited
Indegene Limited has undergone 2 name changes throughout its history. The company was previously known as Ndegene Lifesystems Private Limited, and Indegene Lifesystems Private Limited. The current legal name is Indegene Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Indegene Limited | Current |
| Ndegene Lifesystems Private Limited | Previous |
| Indegene Lifesystems Private Limited | Previous |
CIN History of Indegene Limited
Indegene Limited has 4 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L73100KA1998PLC102040, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L73100KA1998PLC102040 | Current |
| U73100KA1998PTC102040 | Previous |
| U73100MH1998PTC269424 | Previous |
| U73100KA1998PTC032501 | Previous |
| U73100KA1998PLC102040 | Previous |
Associated Brands with Indegene Limited
Indegene Limited operates one associated brand: Indegene. These brands represent Indegene Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Suite solutions are provided for payers and healthcare providers. | indegene.com |
Competitors & Alternatives of Indegene Limited
Brands and companies operating in the same space as Indegene Limited include Zuellig Pharma, IntegriChain, Clinigen and 4 more.
| Competitor | Description | Location | Founded |
|---|---|---|---|
Zuellig Pharma
|
Healthcare access in Asia is enhanced by Zuellig Pharma. | Singapore, Singapore, Singapore | 1992 |
IntegriChain
|
Inventory, order and customer relationship management solution for life science suppliers. | Philadelphia, United States, United States | 2005 |
Clinigen
|
Specialty medicines are supplied via clinical trials and access programs. | Burton-on-trent, United Kingdom, United Kingdom | 2010 |
Fishawack
|
Fully integrated cross-border services are delivered to global pharmaceutical organizations. | Brighton, United Kingdom, United Kingdom | 2001 |
ClearView Healthcare Partners
|
Strategic consulting services are provided to life sciences companies. | Newton, United States, United States | 2008 |
Fabtech
|
Instruments for biotech, pharmaceutical, and biomedical sectors are manufactured. | Mumbai, India, India | 2002 |
Science Group
|
Technology-based consultancy and product development services are provided. | Cambridge, United Kingdom, United Kingdom | 1995 |
Auditor Details of Indegene Limited
Indegene Limited is audited by Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.
| Name | Financial year | Audit opinion |
|---|---|---|
| Deloitte Haskins & Sells (ICAI peer reviewed, certificate valid till 2028-04-30) | FY 2026 | Declaration of unmodified opinion |
Board of Directors of Indegene Limited
Indegene Limited is currently managed by 9 directors, with 13 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
|
Pravin Udhyavara Bhadya Rao
Also directs:
Indegene Limited, Computer Age Management Services Limited, Zensar Technologies Limited and 2 more
|
Director | 08 Jun 2022 | 4 Years 1 Months | Current |
|
Mark Frank Dzialga
Also directs:
Indegene Limited
|
Nominee Director | 16 Apr 2021 | 5 Years 2 Months | Current |
| Ashish Gupta | Director | 28 Apr 2022 | 4 Years 2 Months | Current |
|
Rajesh Bhaskaran Nair
Also directs:
Indegene Limited, Aarabhi Partners Consultants Llp
|
Director | 16 Oct 1998 | 27 Years 8 Months | Current |
|
Manish Gupta
Also directs:
Indegene Limited
|
Whole-Time Director | 11 Feb 2000 | 26 Years 4 Months | Current |
|
Sanjay S Parikh
Also directs:
Indegene Limited
|
Director | 29 Jan 2002 | 24 Years 5 Months | Current |
Financials of Indegene Limited FY 2026 filings available
Indegene Limited reported revenue of ₹3,510.5 Cr (up 23.64% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Revenue from Operations | ₹3,510.5 Cr | ₹2,839.3 Cr | ₹2,589.6 Cr |
| Other Income | ₹72 Cr | ₹107.2 Cr | ₹76.3 Cr |
| Total Income | ₹3,582.5 Cr | ₹2,946.5 Cr | ₹2,665.9 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹2,197.7 Cr | ₹1,815.2 Cr | ₹1,651.6 Cr |
| Finance Costs | ₹19.3 Cr | ₹22 Cr | ₹49.4 Cr |
| Depreciation & Amortisation | ₹126.4 Cr | ₹80.2 Cr | ₹76.1 Cr |
| Other Expenses | ₹693.8 Cr | ₹489.8 Cr | ₹432.6 Cr |
| Total Expenses | ₹3,037.2 Cr | ₹2,407.2 Cr | ₹2,209.7 Cr |
| Profit Before Exceptional Items & Tax | ₹545.3 Cr | ₹539.3 Cr | ₹456.2 Cr |
| Exceptional Items | -₹20.3 Cr | ₹0 | ₹2.4 Cr |
| Profit Before Tax | ₹525 Cr | ₹539.3 Cr | ₹458.6 Cr |
| Total Tax Expense | ₹123.9 Cr | ₹132.6 Cr | ₹121.9 Cr |
| Net Profit | ₹401.1 Cr | ₹406.7 Cr | ₹336.7 Cr |
| attributable to Owners | ₹401.1 Cr | - | ₹344.6 Cr |
| attributable to NCI | ₹0 | - | ₹0 |
| Other Comprehensive Income | ₹139.4 Cr | ₹25.6 Cr | ₹7.9 Cr |
| Total Comprehensive Income | ₹540.5 Cr | ₹432.3 Cr | ₹344.6 Cr |
| EBITDA (computed) | ₹691 Cr | ₹641.5 Cr | ₹581.7 Cr |
| Basic EPS | ₹16.72 | ₹17.15 | ₹15.19 |
| Diluted EPS | ₹16.62 | ₹17.02 | ₹15.07 |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Total Assets | ₹4,620.3 Cr | ₹3,325.9 Cr | ₹2,545.6 Cr |
| Non-current Assets | ₹2,001.9 Cr | ₹795.9 Cr | ₹754.8 Cr |
| Current Assets | ₹2,618.4 Cr | ₹2,530 Cr | ₹1,790.8 Cr |
| Property, Plant & Equipment | ₹194 Cr | ₹134.9 Cr | ₹114.4 Cr |
| Inventories | ₹0 | ₹0 | ₹0 |
| Trade Receivables | ₹981.8 Cr | ₹751.4 Cr | ₹648 Cr |
| Cash & Equivalents | ₹300.8 Cr | ₹241 Cr | ₹188.6 Cr |
| Equity (Net Worth) | ₹3,138.7 Cr | ₹2,615.6 Cr | ₹1,429.1 Cr |
| Equity Share Capital | ₹48.1 Cr | ₹47.9 Cr | ₹44.4 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹333.4 Cr |
| Borrowings (Current) | ₹0 | ₹0 | ₹69.7 Cr |
| Total Debt (computed) | ₹0 | ₹0 | ₹403.1 Cr |
| Current Liabilities | ₹1,086.2 Cr | ₹564.5 Cr | ₹610.9 Cr |
| Total Liabilities | ₹1,481.6 Cr | ₹710.3 Cr | ₹1,116.5 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Operating Cash Flow | ₹650.8 Cr | ₹441.9 Cr | ₹507.7 Cr |
| Investing Cash Flow | -₹512.4 Cr | -₹682.7 Cr | -₹327.2 Cr |
| Financing Cash Flow | -₹82.6 Cr | ₹287.5 Cr | -₹66.2 Cr |
| Capital Expenditure | ₹44.3 Cr | ₹30 Cr | ₹10.7 Cr |
| Free Cash Flow (computed) | ₹606.5 Cr | ₹411.9 Cr | ₹497 Cr |
| Dividends Paid | ₹48 Cr | ₹0 | ₹0 |
| Net Change in Cash | ₹59.8 Cr | ₹52.4 Cr | ₹115 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹1,003.4 Cr | ₹942.1 Cr | ₹804.2 Cr | ₹760.8 Cr | ₹755.6 Cr | ₹720.4 Cr | ₹686.8 Cr | ₹676.5 Cr | ₹673 Cr |
| Other Income | ₹10.8 Cr | ₹19.4 Cr | ₹19.7 Cr | ₹22.1 Cr | ₹25.6 Cr | ₹37.7 Cr | ₹21.4 Cr | ₹22.5 Cr | ₹23.2 Cr |
| Total Income | ₹1,014.2 Cr | ₹961.5 Cr | ₹823.9 Cr | ₹782.9 Cr | ₹781.2 Cr | ₹758.1 Cr | ₹708.2 Cr | ₹699 Cr | ₹696.2 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹632.4 Cr | ₹568 Cr | ₹515.8 Cr | ₹481.5 Cr | ₹485.1 Cr | ₹443.8 Cr | ₹442 Cr | ₹444.3 Cr | ₹428.4 Cr |
| Finance Costs | ₹7.2 Cr | ₹4.6 Cr | ₹3.8 Cr | ₹3.7 Cr | ₹3.1 Cr | ₹3.2 Cr | ₹4 Cr | ₹11.7 Cr | ₹12.3 Cr |
| Depreciation & Amortisation | ₹41.8 Cr | ₹39.6 Cr | ₹23.4 Cr | ₹21.6 Cr | ₹20.7 Cr | ₹20 Cr | ₹19.4 Cr | ₹20.1 Cr | ₹18.5 Cr |
| Other Expenses | ₹207.4 Cr | ₹214.6 Cr | ₹147.8 Cr | ₹124 Cr | ₹123 Cr | ₹144.8 Cr | ₹118.7 Cr | ₹103.3 Cr | ₹105.9 Cr |
| Total Expenses | ₹888.8 Cr | ₹826.8 Cr | ₹690.8 Cr | ₹630.8 Cr | ₹631.9 Cr | ₹611.8 Cr | ₹584.1 Cr | ₹579.4 Cr | ₹565.1 Cr |
| Profit Before Exceptional Items & Tax | ₹125.4 Cr | ₹134.7 Cr | ₹133.1 Cr | ₹152.1 Cr | ₹149.3 Cr | ₹146.3 Cr | ₹124.1 Cr | ₹119.6 Cr | ₹131.1 Cr |
| Exceptional Items | -₹20.3 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹2.4 Cr |
| Profit Before Tax | ₹105.1 Cr | ₹134.7 Cr | ₹133.1 Cr | ₹152.1 Cr | ₹149.3 Cr | ₹146.3 Cr | ₹124.1 Cr | ₹119.6 Cr | ₹133.5 Cr |
| Total Tax Expense | ₹25.4 Cr | ₹31.8 Cr | ₹31 Cr | ₹35.7 Cr | ₹31.7 Cr | ₹36.6 Cr | ₹32.4 Cr | ₹31.9 Cr | ₹38.7 Cr |
| Net Profit | ₹79.7 Cr | ₹102.9 Cr | ₹102.1 Cr | ₹116.4 Cr | ₹117.6 Cr | ₹109.7 Cr | ₹91.7 Cr | ₹87.7 Cr | ₹94.8 Cr |
| attributable to Owners | ₹79.7 Cr | ₹102.9 Cr | ₹0 | ₹116.4 Cr | - | ₹109.7 Cr | ₹91.7 Cr | ₹87.7 Cr | ₹96.6 Cr |
| attributable to NCI | ₹0 | ₹0 | ₹0 | ₹0 | - | ₹0 | ₹0 | ₹0 | ₹0 |
| Other Comprehensive Income | ₹55 Cr | ₹19.3 Cr | ₹48.4 Cr | ₹16.7 Cr | ₹2.6 Cr | ₹13.2 Cr | ₹10.6 Cr | -₹80 Lakh | ₹1.8 Cr |
| Total Comprehensive Income | ₹134.7 Cr | ₹122.2 Cr | ₹150.5 Cr | ₹133.1 Cr | ₹120.2 Cr | ₹122.9 Cr | ₹102.3 Cr | ₹86.9 Cr | ₹96.6 Cr |
| EBITDA (computed) | ₹174.4 Cr | ₹178.9 Cr | ₹160.3 Cr | ₹177.4 Cr | ₹173.1 Cr | ₹169.5 Cr | ₹147.5 Cr | ₹151.4 Cr | ₹161.9 Cr |
| Basic EPS | ₹3.32 | ₹4.29 | ₹4.26 | ₹4.86 | ₹4.91 | ₹4.59 | ₹3.84 | ₹3.79 | ₹4.27 |
| Diluted EPS | ₹3.30 | ₹4.26 | ₹4.23 | ₹4.82 | ₹4.88 | ₹4.55 | ₹3.80 | ₹3.76 | ₹4.24 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Enterprise Medical Solutions | ₹253.7 Cr | ₹67.2 Cr | ₹0 | ₹0 |
| Enterprise Commercial Solutions | ₹719.3 Cr | ₹121.2 Cr | ₹0 | ₹0 |
| Others | ₹30.4 Cr | -₹16.3 Cr | ₹0 | ₹0 |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Enterprise Medical Solutions | ₹929.8 Cr | ₹243.5 Cr | - | - |
| Enterprise Commercial Solutions | ₹2,460.5 Cr | ₹449.2 Cr | - | - |
| Others | ₹120.2 Cr | -₹32.7 Cr | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Revenue from Operations | ₹1,220.6 Cr | ₹1,093.6 Cr | ₹1,045.6 Cr |
| Other Income | ₹78.3 Cr | ₹90.4 Cr | ₹50.3 Cr |
| Total Income | ₹1,298.9 Cr | ₹1,184 Cr | ₹1,095.9 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹795.2 Cr | ₹759.2 Cr | ₹752.3 Cr |
| Finance Costs | ₹8.7 Cr | ₹6.2 Cr | ₹6.6 Cr |
| Depreciation & Amortisation | ₹36.3 Cr | ₹26.2 Cr | ₹31.1 Cr |
| Other Expenses | ₹177.3 Cr | ₹153.9 Cr | ₹125.3 Cr |
| Total Expenses | ₹1,017.5 Cr | ₹945.5 Cr | ₹915.3 Cr |
| Profit Before Exceptional Items & Tax | ₹281.4 Cr | ₹238.5 Cr | ₹180.6 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹281.4 Cr | ₹238.5 Cr | ₹180.6 Cr |
| Total Tax Expense | ₹69.5 Cr | ₹57.2 Cr | ₹42.7 Cr |
| Net Profit | ₹211.9 Cr | ₹181.3 Cr | ₹137.9 Cr |
| Other Comprehensive Income | -₹2.8 Cr | -₹1.3 Cr | -₹4.6 Lakh |
| Total Comprehensive Income | ₹209.1 Cr | ₹180 Cr | ₹137.85 Cr |
| EBITDA (computed) | ₹326.4 Cr | ₹270.9 Cr | ₹218.3 Cr |
| Basic EPS | ₹8.83 | ₹7.64 | ₹6.22 |
| Diluted EPS | ₹8.78 | ₹7.59 | ₹6.17 |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Total Assets | ₹2,481.9 Cr | ₹2,149.7 Cr | ₹1,220.3 Cr |
| Non-current Assets | ₹1,207 Cr | ₹931.7 Cr | ₹469.3 Cr |
| Current Assets | ₹1,274.9 Cr | ₹1,218 Cr | ₹751 Cr |
| Property, Plant & Equipment | ₹112.6 Cr | ₹52.8 Cr | ₹56.1 Cr |
| Inventories | ₹0 | ₹0 | ₹0 |
| Trade Receivables | ₹288.4 Cr | ₹418.4 Cr | ₹378 Cr |
| Cash & Equivalents | ₹48.5 Cr | ₹35.2 Cr | ₹13.2 Cr |
| Equity (Net Worth) | ₹2,080.5 Cr | ₹1,888.2 Cr | ₹953.8 Cr |
| Equity Share Capital | ₹48.1 Cr | ₹47.9 Cr | ₹44.4 Cr |
| Borrowings (Non-current) | ₹0 | ₹0 | ₹0 |
| Borrowings (Current) | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹0 | ₹0 | ₹0 |
| Current Liabilities | ₹273.8 Cr | ₹189.5 Cr | ₹198.1 Cr |
| Total Liabilities | ₹401.4 Cr | ₹261.5 Cr | ₹266.5 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 |
|---|---|---|---|
| Operating Cash Flow | ₹345.6 Cr | ₹129 Cr | ₹176.2 Cr |
| Investing Cash Flow | -₹272.1 Cr | -₹824.7 Cr | -₹187.7 Cr |
| Financing Cash Flow | -₹62.6 Cr | ₹717.3 Cr | -₹15.8 Cr |
| Capital Expenditure | ₹44.1 Cr | ₹16.5 Cr | ₹9.9 Cr |
| Free Cash Flow (computed) | ₹301.5 Cr | ₹112.5 Cr | ₹166.3 Cr |
| Dividends Paid | ₹48 Cr | ₹0 | ₹0 |
| Net Change in Cash | ₹13.3 Cr | ₹22 Cr | -₹28.6 Cr |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹368.2 Cr | ₹290.1 Cr | ₹306.7 Cr | ₹255.6 Cr | ₹266.7 Cr | ₹286.7 Cr | ₹281.7 Cr | ₹258.6 Cr | ₹272.5 Cr |
| Other Income | ₹6.1 Cr | ₹22.6 Cr | ₹17.5 Cr | ₹32.1 Cr | ₹35.2 Cr | ₹22.3 Cr | ₹22.4 Cr | ₹13.7 Cr | ₹23.1 Cr |
| Total Income | ₹374.3 Cr | ₹312.7 Cr | ₹324.2 Cr | ₹287.7 Cr | ₹301.9 Cr | ₹309 Cr | ₹304.1 Cr | ₹272.3 Cr | ₹295.6 Cr |
| Cost of Materials Consumed | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Employee Benefit Expense | ₹213.4 Cr | ₹201.9 Cr | ₹198.3 Cr | ₹181.6 Cr | ₹184.5 Cr | ₹192.2 Cr | ₹197.1 Cr | ₹185.3 Cr | ₹194.9 Cr |
| Finance Costs | ₹3.1 Cr | ₹1.8 Cr | ₹2 Cr | ₹1.7 Cr | ₹1.5 Cr | ₹1.6 Cr | ₹1.6 Cr | ₹1.5 Cr | ₹1.5 Cr |
| Depreciation & Amortisation | ₹10.9 Cr | ₹9.5 Cr | ₹8.6 Cr | ₹7.3 Cr | ₹6.9 Cr | ₹6.5 Cr | ₹6.2 Cr | ₹6.6 Cr | ₹7.6 Cr |
| Other Expenses | ₹51.7 Cr | ₹50.5 Cr | ₹37.8 Cr | ₹37.3 Cr | ₹42.6 Cr | ₹42.6 Cr | ₹38.2 Cr | ₹33.8 Cr | ₹31.2 Cr |
| Total Expenses | ₹279.1 Cr | ₹263.7 Cr | ₹246.7 Cr | ₹227.9 Cr | ₹235.5 Cr | ₹242.9 Cr | ₹243.1 Cr | ₹227.2 Cr | ₹235.2 Cr |
| Profit Before Exceptional Items & Tax | ₹95.2 Cr | ₹49 Cr | ₹77.5 Cr | ₹59.8 Cr | ₹66.4 Cr | ₹66.1 Cr | ₹61 Cr | ₹45.1 Cr | ₹60.4 Cr |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹95.2 Cr | ₹49 Cr | ₹77.5 Cr | ₹59.8 Cr | ₹66.4 Cr | ₹66.1 Cr | ₹61 Cr | ₹45.1 Cr | ₹60.4 Cr |
| Total Tax Expense | ₹23.1 Cr | ₹14.2 Cr | ₹17.6 Cr | ₹14.7 Cr | ₹12.2 Cr | ₹16.2 Cr | ₹16.2 Cr | ₹12.5 Cr | ₹11.5 Cr |
| Net Profit | ₹72.1 Cr | ₹34.8 Cr | ₹59.9 Cr | ₹45.1 Cr | ₹54.2 Cr | ₹49.9 Cr | ₹44.8 Cr | ₹32.6 Cr | ₹48.9 Cr |
| Other Comprehensive Income | -₹5.9 Cr | ₹50 Lakh | ₹1.8 Cr | ₹90 Lakh | -₹2.4 Cr | ₹80 Lakh | -₹40 Lakh | ₹70 Lakh | -₹30 Lakh |
| Total Comprehensive Income | ₹66.2 Cr | ₹35.3 Cr | ₹61.7 Cr | ₹46 Cr | ₹51.8 Cr | ₹50.7 Cr | ₹44.4 Cr | ₹33.3 Cr | ₹48.6 Cr |
| EBITDA (computed) | ₹109.2 Cr | ₹60.3 Cr | ₹88.1 Cr | ₹68.8 Cr | ₹74.8 Cr | ₹74.2 Cr | ₹68.8 Cr | ₹53.2 Cr | ₹69.5 Cr |
| Basic EPS | ₹3.00 | ₹1.45 | ₹2.50 | ₹1.88 | ₹2.26 | ₹2.09 | ₹1.88 | ₹1.41 | ₹2.20 |
| Diluted EPS | ₹2.98 | ₹1.44 | ₹2.48 | ₹1.87 | ₹2.25 | ₹2.07 | ₹1.86 | ₹1.39 | ₹2.19 |
Shareholding Pattern of Indegene Limited
As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 0.00%, foreign institutional investors hold 10.27%, domestic institutional investors hold 8.30%, retail and other public shareholders hold 81.44% of Indegene Limited. The company had 142,119 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Mar 2026 | Mar 2025 | |
|---|---|---|
| Promoters | 0.00% | 0.00% |
| Public | 100.00% | 100.00% |
| Promoter change (YoY, %pts) | +0.00 | - |
Board & Governance of Indegene Limited
As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Indegene Limited has 11 directors - 7 independent and 2 executive. The board is chaired by Manish Gupta.
| Director | Position | On board since | Listed boards |
|---|---|---|---|
| Manish Gupta | Executive Director · CEO · Chairperson | 2000-02-11 | 1 |
| Sanjay Suresh Parikh | Executive Director | 2002-01-29 | 1 |
| Rajesh Bhaskaran Nair | Non-Executive - Non Independent Director | 1998-10-16 | 1 |
| Mark Francis Dzialga | Non-Executive - Non Independent Director | 2021-04-16 | 1 |
| Krishnamurthy Venugopala Tenneti | Non-Executive - Independent Director | 2022-07-28 | 2 |
| Ashish Gupta | Non-Executive - Independent Director | 2022-04-28 | 3 |
| Jairaj Manohar Purandare | Non-Executive - Independent Director | 2022-04-28 | 4 |
| Pravin Udhyavara Bhadya Rao | Non-Executive - Independent Director | 2022-06-08 | 4 |
| Georgia Nikolakopoulou Papathomas | Non-Executive - Independent Director | 2022-09-30 | 1 |
| Neeraj Bharadwaj | Non-Executive - Independent Director | 2026-01-23 | 2 |
| Jill Mary De Simone | Non-Executive - Independent Director | 2026-01-22 | 1 |
| Committee | Members |
|---|---|
| Audit Committee | Jairaj Manohar Purandare (Chairperson), Sanjay Suresh Parikh, Pravin Udhyavara Bhadya Rao, Krishnamurthy Venugopala Tenneti |
| Nomination and remuneration committee | Krishnamurthy Venugopala Tenneti (Chairperson), Pravin Udhyavara Bhadya Rao, Mark Francis Dzialga, Ashish Gupta, Jairaj Manohar Purandare, Neeraj Bharadwaj |
| Stakeholders Relationship Committee | Jairaj Manohar Purandare (Chairperson), Sanjay Suresh Parikh, Rajesh Bhaskaran Nair |
| Risk Management Committee | Manish Gupta (Chairperson), Rajesh Bhaskaran Nair, Sanjay Suresh Parikh, Pravin Udhyavara Bhadya Rao |
| Corporate Social Responsibility Committee | Manish Gupta (Chairperson), Rajesh Bhaskaran Nair, Sanjay Suresh Parikh, Pravin Udhyavara Bhadya Rao |
| Investment Committee | Krishnamurthy Venugopala Tenneti (Chairperson), Ashish Gupta, Mark Francis Dzialga, Rajesh Bhaskaran Nair, Neeraj Bharadwaj |
Charges & Borrowings of Indegene Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 27 Sep 2024 | Jp Morgan Chase Bank, N.A. | ₹15 Cr | Open |
| 29 Aug 2022 | Citi Bank N.A. | ₹15 Cr | Open |
| 26 May 2022 | Others | ₹10 Cr | Open |
| 20 Dec 2021 | The Hongkong and Shanghai Banking Corporation Limited | ₹15 Cr | Open |
| 21 Jun 2012 | Others | ₹30.5 Cr | Open |
Total charge records: 9 View all charges
Employees and EPFO Compliance at Indegene Limited
Indegene Limited has a workforce of 4,628 employees as of Apr 07, 2024.
Employee Count & EPFO Data of Indegene Limited
Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.
GST Compliance of Indegene Limited
GSTIN & GST Filing Data of Indegene Limited
Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.
Credit Ratings, Litigation & Regulatory Alerts for Indegene Limited
Credit Ratings, Legal Cases & Regulatory Alerts of Indegene Limited
Access complete credit rating history, litigation records, regulatory alerts, and compliance data.
MSME Payment Delays by Indegene Limited
MSME Payment Delays by Indegene Limited
Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.
Subsidiaries & Group Companies of Indegene Limited
Subsidiaries & Group Companies of Indegene Limited
See the full corporate group - holding company, subsidiaries, associates and joint ventures of Indegene Limited with ownership details.
MCA Filings & Documents of Indegene Limited
MCA Filings & Documents of Indegene Limited
Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.
Recent Activity on Indegene Limited
Recent News on Indegene Limited
Frequently Asked Questions about Indegene Limited
Indegene Limited is an active public limited company in the travel and hospitality sector based in Bangalore, Karnataka, India. It was incorporated on 16 October 1998 (28+ years old) and is registered under CIN L73100KA1998PLC102040. The company has 4,628 employees.
Indegene Limited reported revenue of ₹2,946.5 Cr for FY 2025 (up 11.00% YoY).
The current directors of Indegene Limited are:
The primary industry of Indegene Limited is travel and hospitality. The company specifically operates in consumer professional services. The company is currently active in this sector.
Yes, Indegene Limited is a listed company.
Indegene Limited can be reached at the registered office: Aspen G4 3Rd Floor Manyata Embassy Business Park Outer Ring Road Nagavara, Bangalore, Karnataka, India – 560045, or through the website indegene.com.